United States Patent 8,067,437: Indacaterol COPD Treatment Claims, Scope, Expiration, and Patent Landscape

US Patent No. 8,067,437 is a Novartis patent covering the use of indacaterol, including indacaterol maleate, to treat chronic obstructive pulmonary disease. Its central protection is a method-of-treatment claim. The patent is not limited in claim 1 to inhalation, once-daily dosing, a specific device, or a particular pharmaceutical formulation. Those limitations appear only in dependent claims.

The patent’s projected expiration is June 29, 2027, based on its earliest claimed priority date and the standard 20-year patent term. The patent was directed to the COPD indication for indacaterol, marketed in the United States as Arcapta Neohaler. It is distinct from patents directed primarily to the chemical compound, inhalation formulations, capsules, devices, or manufacturing processes.

What drug does US Patent 8,067,437 protect?

The compound identified in the claims is indacaterol, specifically the R-enantiomer of the quinolinone-based long-acting beta2-adrenergic agonist.

The marketed active pharmaceutical ingredient is generally supplied as indacaterol maleate. The claimed chemical structure corresponds to:

Indacaterol free base
Indacaterol salts
Indacaterol solvates
Indacaterol maleate

Indacaterol is a long-acting bronchodilator used for maintenance treatment of airflow obstruction in COPD. It is not an inhaled corticosteroid, muscarinic antagonist, biologic, or rescue bronchodilator.

The FDA approved Arcapta Neohaler for once-daily maintenance treatment of COPD under NDA 022383. The product contains indacaterol maleate inhalation powder in capsules administered through the Neohaler device. [2]

What are the claims of US Patent 8,067,437?

The claims cover both the therapeutic use of indacaterol and selected administration formats.

Claim	Subject matter	Principal limitation
1	Treatment of COPD	Administering an effective amount of indacaterol in free, salt, or solvate form
2	Salt form	Indacaterol administered as a salt
3	Maleate salt	Indacaterol maleate
4	Dosing frequency	Once-a-day administration
5	Pharmaceutical composition	Indacaterol plus a pharmaceutically acceptable carrier
6	Salt form	Indacaterol administered as a salt
7	Maleate salt	Indacaterol maleate
8	Inhalable composition	Pharmaceutical composition in inhalable form
9	Inhalation device	Administration using an inhalation device
10	Dosing frequency	Once-a-day administration

Claims 6 and 7, as reproduced, repeat the substance of claims 2 and 3 while depending on claim 1. Claims 8 and 9 also contain dependency language referring to "any claim 1," which appears to be an imprecise transcription or claim-drafting issue. The enforceable scope must be determined from the issued patent document and its prosecution history, rather than from an unofficial claim transcription.

How broad is claim 1 of US 8,067,437?

Claim 1 is the broadest therapeutic claim. It requires:

A subject in need of treatment;
Chronic obstructive pulmonary disease;
Administration of an effective amount; and
The specified R-enantiomer of indacaterol in free, salt, or solvate form.

Claim 1 does not expressly require:

Inhalation;
A once-daily schedule;
Indacaterol maleate;
A particular dose;
A specific capsule;
A specific inhaler;
A particular particle-size distribution;
A defined excipient;
A particular COPD severity classification; or
Monotherapy.

The broadest plausible infringement theory would therefore involve a product containing indacaterol that is labeled or promoted for COPD treatment, regardless of whether the product is supplied as free base, maleate, another salt, or a solvate.

The claim still requires a therapeutic method. Mere possession or manufacture of indacaterol is not, by itself, infringement of claim 1. A generic sponsor would face greater exposure if its label instructs use for COPD, particularly once-daily maintenance treatment.

What formulations are protected by US Patent 8,067,437?

The patent provides formulation-related protection through claim 5 and the dependent claims that follow it. Claim 5 covers a COPD treatment method using a pharmaceutical composition containing:

An effective amount of indacaterol in free, salt, or solvate form; and
A pharmaceutically acceptable carrier.

Claims 8 and 9 narrow the formulation and delivery route to inhalable administration and use of an inhalation device.

The formulation protection is relatively functional. The claims do not, based on the supplied language, require:

A specific carrier;
Lactose or another named excipient;
A capsule;
A powder formulation;
A metered-dose inhaler;
A dry-powder inhaler;
A nebulizer;
A particular inhaler architecture; or
A specific dose strength.

Those features may be covered by separate formulation, capsule, device, or delivery patents. Patent 8,067,437 should therefore be analyzed as an indication and treatment-regimen patent, not as the complete Arcapta product patent estate.

Does US Patent 8,067,437 cover once-daily indacaterol?

Yes. Claims 4 and 10 expressly address once-daily administration.

The once-daily claims are narrower than claim 1 because they require a specific dosing frequency. They are commercially important because the FDA-approved Arcapta product was labeled for once-daily maintenance treatment. [2]

A generic product with a COPD label and once-daily instructions would present a direct claim-mapping risk under the once-daily claims. A product with a different dosing schedule could avoid claims 4 and 10, but it would still need to assess claim 1 and other patent claims covering the compound, formulation, or COPD use.

What is the patent expiration date for US 8,067,437?

The standard projected expiration date is June 29, 2027.

Item	Date or status
Patent	US 8,067,437
Patent holder/assignee	Novartis-related entity
Technology	Indacaterol treatment of COPD
Earliest priority basis	June 29, 2007
FDA product associated with the patent	Arcapta Neohaler
Standard patent expiration	June 29, 2027
Patent term adjustment	Must be confirmed from the USPTO patent record
Patent term extension	No extension is assumed in the standard expiration calculation
Regulatory exclusivity	Separate from patent term

Patent expiration and FDA regulatory exclusivity are different rights. The three-year new clinical investigation exclusivity associated with the original approval did not extend to 2027 and did not prevent later ANDA activity after the regulatory exclusivity period ended. [2][3]

What is the Orange Book status of US Patent 8,067,437?

US Patent 8,067,437 has been associated with the Arcapta Neohaler patent listing and the indacaterol COPD indication. Orange Book status should be assessed by product and NDA, because FDA listings can change through patent delisting, expiration updates, and regulatory submissions.

The relevant regulatory relationship is:

Regulatory issue	Assessment
NDA	022383
Brand	Arcapta Neohaler
Active ingredient	Indacaterol maleate
Dosage form	Inhalation powder
Orange Book relevance	Method-of-use and product-related patent listings
FDA exclusivity	Expired separately from the patent term
ANDA pathway	Applicable to a chemically synthesized active ingredient
BLA pathway	Not applicable

A listing in the Orange Book does not establish that every claim is valid or infringed. It gives the patent holder an FDA-linked mechanism for receiving notice of an ANDA certification and, if appropriate, filing an infringement action under the Hatch-Waxman framework. [3][4]

How does a Paragraph IV challenge affect this patent?

A generic applicant seeking approval before the patent’s expiration could submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed. If the NDA holder receives proper notice and files an infringement action within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments. [4]

For this patent, the principal Paragraph IV theories would likely focus on:

Non-infringement

A generic applicant could argue that its proposed label does not instruct:

Treatment of COPD;
Once-daily administration;
Use of indacaterol maleate; or
Use with an inhalation device within the relevant claim scope.

A skinny label removing the patented COPD indication could reduce direct label-based infringement exposure. That strategy would not eliminate risk if the remaining label, promotional materials, physician instructions, or product design induce the patented use.

Invalidity for obviousness

Potential obviousness arguments would examine whether a skilled person would have reasonably expected the claimed R-indacaterol compound to provide effective COPD treatment, particularly in a once-daily inhaled formulation. Relevant prior art could include:

Earlier indacaterol compound patents;
Other long-acting beta2 agonists;
COPD treatment guidelines;
Preclinical and clinical studies;
Known inhaled bronchodilator regimens; and
Evidence relating to duration of action and enantiomer selection.

The strongest defense would require a prior-art combination that teaches the claimed compound, COPD treatment, and the relevant administration strategy with a reasonable expectation of success. General knowledge that beta2 agonists treat obstructive airway disease would not automatically establish obviousness of a particular compound and regimen.

Written description and enablement

Claim 1 covers free form, salts, and solvates, while the specification must support the full genus and the COPD treatment method. A challenge could target whether the disclosure adequately supports all claimed forms and enables effective treatment across the claim’s full scope.

Because the claim identifies a specific compound rather than an open-ended chemical genus, a written-description challenge would generally be narrower than one directed to a broad Markush claim. The claim’s therapeutic breadth remains relevant to enablement, especially if the specification contains limited clinical or pharmacological support.

Double patenting

The patent estate may contain overlapping compound, use, formulation, and dosing patents. Obviousness-type double-patenting issues would depend on the relationship between the claims of this patent and related Novartis patents, terminal disclaimers, and the prosecution history.

Which companies are likely to challenge indacaterol patent protection?

Indacaterol is a small-molecule product, so the competitive threat comes from ANDA applicants rather than biosimilar developers. Potential challengers would include generic companies with expertise in:

Dry-powder inhalers;
Inhalation capsules;
Device-drug combinations;
Complex generics;
Beta2-agonist products; and
Regulatory exclusivity challenges.

The key commercial obstacle is not only the active ingredient. A generic applicant must develop a therapeutically equivalent inhalation product and satisfy FDA requirements for the drug-device combination. That can reduce the number of practical competitors relative to ordinary oral tablets.

A public litigation search should distinguish among:

Cases specifically naming US 8,067,437;
Cases involving other Arcapta patents;
ANDA cases concerning indacaterol products;
Patent ownership or licensing disputes; and
Regulatory disputes involving FDA listing or approval.

A lawsuit involving another indacaterol patent does not establish that US 8,067,437 was asserted, adjudicated, or invalidated.

What patent litigation affects Arcapta and indacaterol?

The relevant litigation risk is distributed across the product estate rather than concentrated in a single patent. A generic applicant may challenge several patents in one ANDA notice, including:

The active compound patent;
The COPD method patent;
The once-daily dosing patent;
The inhalation formulation patent;
The capsule patent;
The inhaler-device patent; and
Manufacturing or particle-engineering patents.

For US 8,067,437, the central litigation questions would be whether the proposed generic label induces COPD treatment and whether the claims are valid in view of prior indacaterol and long-acting beta2-agonist disclosures.

Settlement terms, if any, would control the commercial entry date. A patent settlement can permit an agreed launch before the listed expiration date, subject to antitrust review, FTC reporting requirements, and the terms of the specific agreement. A settlement involving a different Arcapta patent does not necessarily resolve this patent.

How strong is the patent estate for indacaterol?

The patent estate has moderate-to-strong practical protection when viewed as a portfolio, but US 8,067,437 alone is narrower than the full commercial barrier.

Protection layer	Function	Practical importance
Compound patent	Protects indacaterol chemical structure	Highest early-life protection
COPD method patent	Protects treatment of COPD with indacaterol	Important against labeled generic use
Once-daily claims	Protects the approved dosing schedule	Strong label-matching relevance
Maleate claims	Protects the marketed salt in the claimed method	Relevant to Arcapta composition
Inhalation claims	Protects inhalable administration	Relevant to the approved route
Formulation patents	Protect powder, excipients, and performance	Can delay or complicate generic approval
Device patents	Protect inhaler architecture and delivery system	Important for device substitution
Manufacturing patents	Protect particle production and drug delivery properties	Can create non-patentability and freedom-to-operate barriers

The strength of US 8,067,437 depends on claim construction, prosecution history, prior art, and the proposed generic label. Its commercial value is highest against a product that copies the approved Arcapta use: inhaled indacaterol maleate, administered once daily for COPD through an inhalation device.

Is there biosimilar risk for indacaterol?

No. Indacaterol is a chemically synthesized small molecule. The relevant competitors would file ANDAs, not abbreviated biosimilar applications under the Public Health Service Act.

The product can still present complex-generic issues because FDA may evaluate the inhaler, capsule, powder performance, delivered dose, and device-user interface. Those issues create development and regulatory barriers, but they do not convert the product into a biologic.

What generic launch scenarios exist for indacaterol?

Potential launch scenarios fall into four categories.

Launch after patent expiry

A generic applicant may launch after the relevant patents expire, subject to FDA approval and any remaining regulatory requirements. For US 8,067,437, the standard date is June 29, 2027.

Launch after a successful Paragraph IV challenge

If the patent is held invalid or not infringed, approval and launch may occur before the nominal expiration date, subject to other listed patents.

Authorized generic or licensed entry

Novartis could authorize a third party to market an equivalent product or license technology. Commercial entry would depend on the agreement and applicable competition rules.

Settlement-based entry

A settlement could establish a negotiated launch date. The date may be earlier than the patent expiration but later than the generic applicant’s preferred launch date.

A generic applicant must clear the entire relevant Orange Book and patent portfolio. Defeating US 8,067,437 alone would not necessarily permit immediate market entry if another valid, enforceable Arcapta patent remains listed and applicable.

What geographic coverage does US 8,067,437 provide?

US 8,067,437 provides rights only in the United States. It does not directly control indacaterol use in Europe, Canada, Japan, China, or other jurisdictions.

The international landscape may include corresponding national patents covering:

Indacaterol;
COPD treatment;
Once-daily administration;
Indacaterol maleate;
Inhalation formulations; and
Inhaler devices.

Each jurisdiction requires separate analysis of claim scope, prosecution amendments, patent term, supplementary protection certificates, regulatory exclusivity, and litigation. A U.S. expiration date cannot be transferred to foreign jurisdictions.

What manufacturing and intellectual-property barriers affect generic indacaterol?

The principal manufacturing barriers are technical rather than chemical. A competing product may need to reproduce or design around:

Stable indacaterol maleate powder;
Appropriate aerodynamic particle-size distribution;
Consistent capsule emptying;
Dose uniformity;
Moisture control;
Delivered-dose performance;
Device resistance and airflow characteristics;
Container-closure protection; and
Inhaler usability.

These issues may be covered by separate patents or may create FDA equivalence challenges even when the underlying compound is no longer protected. Freedom-to-operate analysis should therefore review the full patent family, not only US 8,067,437.

How does US 8,067,437 compare with other COPD drug patents?

US 8,067,437 is an indication-and-regimen patent. Its structure differs from patents covering other major COPD products.

Patent type	Typical protected subject matter	Relevance to indacaterol
Compound patent	Molecular structure	May block active-ingredient substitution
Method patent	Treatment of COPD	Directly relevant to claim 1
Regimen patent	Once-daily or other dosing schedule	Relevant to claims 4 and 10
Formulation patent	Powder, capsule, excipient, or dose	Relevant to Arcapta product design
Device patent	Inhaler construction	Relevant to Neohaler-type delivery
Biologic patent	Antibody or recombinant protein	Not relevant to indacaterol
Combination patent	LABA/LAMA or LABA/ICS combinations	Separate from indacaterol monotherapy

Indacaterol’s competitive set includes other long-acting bronchodilators such as salmeterol, formoterol, olodaterol, vilanterol, glycopyrrolate, tiotropium, and umeclidinium. Those products have separate patent estates and do not generally avoid infringement merely because they are pharmacologically different.

What is the revenue exposure from this patent?

US 8,067,437 protects a major commercial use of indacaterol, but the patent’s revenue exposure depends on the broader Arcapta franchise.

The principal revenue risks are:

Generic substitution after patent expiry;
Earlier entry following a Paragraph IV success;
Loss of once-daily differentiation;
Competition from long-acting muscarinic antagonists;
Combination products containing other long-acting bronchodilators;
Limited market uptake of indacaterol monotherapy; and
Device or formulation barriers that delay generic competition.

The patent has greater value when combined with formulation and device patents. Once those barriers expire or are successfully challenged, the method patent may remain relevant to approval strategy but may be easier to design around through label restrictions or alternative dosing instructions.

Key Takeaways

US 8,067,437 covers COPD treatment with indacaterol, including its free base, salts, solvates, and maleate salt.
Claim 1 is the broadest claim and is not expressly limited to inhalation or once-daily dosing.
Claims 4 and 10 specifically cover once-daily administration.
Claims 5, 8, and 9 address compositions, inhalable forms, and inhalation devices.
The standard projected expiration date is June 29, 2027.
The patent is relevant to Arcapta Neohaler, NDA 022383.
Indacaterol is a small molecule, so generic risk arises through ANDA litigation, not biosimilar litigation.
A Paragraph IV challenge could assert non-infringement, obviousness, written-description, enablement, or double-patenting defenses.
Defeating this patent would not necessarily clear other Arcapta compound, formulation, capsule, device, or manufacturing patents.
The principal commercial risk is a generic inhaled indacaterol maleate product with a COPD and once-daily label.

Frequently Asked Questions

Does US 8,067,437 cover indacaterol maleate itself?

No. The claims cover methods of treating COPD using indacaterol maleate. A separate compound or composition patent would be needed to claim the salt as a product independent of the treatment method.

Can a generic indacaterol product avoid US 8,067,437 by using a different inhaler?

Possibly, but a different device would not avoid claim 1 if the generic product still instructs administration of indacaterol for COPD. It could be more relevant to claims 8 and 9 and to separate device patents.

Does the patent cover treatment of asthma?

The supplied claims are limited to treatment of chronic obstructive pulmonary disease. They do not expressly cover asthma treatment.

Is once-daily dosing required for infringement of claim 1?

No. Claim 1 does not contain a once-daily limitation. Once-daily administration is addressed separately in claims 4 and 10.

What is the key freedom-to-operate issue for a generic indacaterol developer?

The key issue is whether the proposed product, label, device, formulation, and manufacturing process fall within the full Arcapta patent portfolio, including US 8,067,437 and separate patents directed to indacaterol products and inhalation delivery.

References

United States Patent No. 8,067,437. (2011). Use of indacaterol for the treatment of COPD. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2011). Arcapta Neohaler (indacaterol maleate) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.
U.S. Food and Drug Administration. (n.d.). ANDA submissions: Refuse-to-receive standards. FDA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9913083.3	Jun 04, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1183240	⤷ Start Trial	C300437	Netherlands	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	CA 2010 00006	Denmark	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	91651	Luxembourg	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC009/2010	Ireland	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	10C0006	France	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC/GB10/009	United Kingdom	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	C01183240/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,067,437

Summary for Patent: 8,067,437